RT Book, Section A1 COHEN, VICTOR A1 JELLINEK-COHEN, SAMANTHA P. A2 Cohen, Henry SR Print(0) ID 1112259069 T1 Procainamide T2 Casebook in Clinical Pharmacokinetics and Drug Dosing YR 2015 FD 2015 PB McGraw-Hill Education PP New York, NY SN 9780071628358 LK accesspharmacy.mhmedical.com/content.aspx?aid=1112259069 RD 2024/03/29 AB Procainamide was introduced in 1951 as a Class 1a antiarrhythmic agent. Class 1a antiarrythmics, the oldest class of antiarrythmics on the market, are considered membrane-stabilizing agents that work by blocking sodium channels. Agents in this class include quinidine, procainamide, and disopyramide. Although these agents are quite effective in suppressing both atrial and ventricular ectopy, they are associated with significant toxicity, and thus, their use has fallen out of favor. Procainamide is indicated for the treatment of life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.1 Off-label uses of procainamide include conversion of atrial fibrillation/flutter to sinus rhythm.1,2